Results 11 to 20 of about 13,963,189 (308)

Second-Line Therapy for Advanced NSCLC [PDF]

The Oncologist, 2013
Abstract Most patients with lung cancer have non-small cell lung cancer (NSCLC) subtype and have advanced disease at the time of diagnosis. Improvements in both first-line and subsequent therapies are allowing longer survival and enhanced quality of life for these patients.
Jared M, Weiss, Thomas E, Stinchcombe
openaire   +4 more sources

Predictive Factors for Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis [PDF]

Journal of Kidney Cancer and VHL, 2017
Currently, about 50% of patients with metastatic renal cell carcinoma (mRCC) receive a second-line therapy. Therefore, the choice at each subsequent treatment line remains an important issue.
Hendrik Eggers, Philipp Ivanyi, Mareike Hornig, Viktor Grünwald   +3 more
doaj   +2 more sources

Isolated Limb Infusion as First, Second, or Third or Later-Line Therapy for Metastatic In-Transit Melanoma

Cancer Control
Background Ten percent of patients with melanoma develop in-transit metastases (ITM). Isolated limb infusion (ILI) is a well-established therapy for unresectable ITM on the extremities, but the ideal sequencing/line of therapy of ILI has not been defined.
Aleena Boby BA, Michelle M. Dugan MD, Helana Ghali BS, Shaliz Aflatooni BS, Danielle K. DePalo MD, Wenyi Fan MSPH, Jonathan S. Zager MD   +6 more
doaj   +3 more sources

Valganciclovir as Add-on to Second-Line Therapy in Patients with Recurrent Glioblastoma [PDF]

, 2022
Glioblastoma invariably recurs despite aggressive and multimodal first-line treatment and no standardized second-line therapy exists. We previously reported that treatment with the antiviral drug valganciclovir as an add-on to standard therapy ...
Afsar Rahbar, Mattia Russel Pantalone, Cecilia Söderberg-Naucler, Giuseppe Stragliotto   +3 more
core   +2 more sources

Second-line therapies in immune thrombocytopenia [PDF]

Hematology, 2016
Abstract Immune thrombocytopenia (ITP) is a rare, acquired autoimmune condition characterized by a low platelet count and an increased risk of bleeding. Although many children and adults with ITP will not need therapy beyond historic first-line treatments of observation, steroids, intravenous immunoglobulin (IVIG), and anti-D globulin,
Rachael F, Grace, Cindy, Neunert
openaire   +2 more sources

Immunological failure of first-line and switch to second-line antiretroviral therapy among HIV-infected persons in Tanzania: analysis of routinely collected national data. [PDF]

, 2015
OBJECTIVES: Rates of first-line treatment failure and switches to second-line therapy are key indicators for national HIV programmes. We assessed immunological treatment failure defined by WHO criteria in the Tanzanian national HIV programme. METHODS: We
Ramadhani, Angela, Vanobberghen, Fiona M, Mmbando, Donan, Wringe, Alison, Todd, Jim, Zaba, Basia, Kilama, Bonita   +6 more
core   +1 more source

Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda. [PDF]

, 2014
We investigated phenotypic and genotypic resistance after 2 years of first-line therapy with two HIV treatment regimens in the absence of virological ...
Awio, P., Munderi, P., Pillay, D., Ndembi, N., Nkurunziza, P., Ndembi, N, Pattery, T, Dunn, DT, van Cauwenberge, A, Gilks, C. F., Gilks, CF, Awio, P, Munderi, P, Nkurunziza, P, Kaleebu, P., Pillay, D, Goodall, RL, DART Virology Group and Trial Teams, Kaleebu, P, Goodall, R. L., Kityo, C., Dunn, D. T., Kityo, C, Pattery, T., van Cauwenberge, A., K. Mataruka, B. Kikaire, M. Nabankkema, H. Grosskurth, P. Khauka, M. Namyalo, C. Kityo, C. Parry, C. F. Gilks, M. Spyer, R. Magala, P. Kaleebu, R. L. Goodall, P. Nkurunziza, N. Ndembi, R. Goodall, A. Zalwango, T. Pattery, L. Generous, P. Awio, D. Dunn, D. Pillay, K. Fadhiru, G. Kabuye, L. Mugarura, G. Nassuna, M. Chirara, M. Katuramur, B. Magambo, J. Nkalubo, R. Massa, A. van Cauwenberge, E. Zalwango, V. Robertson, P. Munderi, D. Yirrell, R. Kasirye, D. M. Gibb, A. Kapaata, D. T. Dunn, D. Nsibambi, F. Lyagoba, T. Musunga, A.L. McCormick, M. Nakazibwe, C. Gilks   +70 more
core   +1 more source

Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration [PDF]

, 2011
Article approval pendingWith expanding pediatric antiretroviral therapy (ART) access, children will begin to experience treatment failure and require second-line therapy. We evaluated the probability and determinants of virologic failure and switching in
Technau K., Olivia Keiser, Rabie, Helena, Giddy, Janet, Egger, Matthias, Davies M.-A., Eley, Brian, Van Cutsem, Gilles, Harry Moultrie, Janet Giddy, Karl Technau, Moultrie H., Helena Rabie, Eley B., Giddy J., Egger M., Robin Wood, Technau, Karl, Rabie H., Van Cutsem G., Gilles Van Cutsem, Matthias Egger, Keiser, Olivia, Brian Eley, Moultrie, Harry, Boulle, Andrew, Mary-Ann Davies, Davies, Mary-Ann, Andrew Boulle, Boulle A., Keiser O., Wood R., Wood, Robin   +32 more
core   +3 more sources

Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. [PDF]

, 2009
In high-income countries, viral load is routinely measured to detect failure of antiretroviral therapy (ART) and guide switching to second-line ART. Viral load monitoring is not generally available in resource-limited settings. We examined switching from
Sprinz, Eduardo, Egger, Matthias, Wood, R, Tuboi, Suely, Kumarasamy, N, Braitstein, Paula, Kumarasamy, Nagalingeswaran, Schecter, Mauro, Nash, D, Calmy, Alexandra, Brinkhof, Martin W G, Jahn, Andreas, Schechter, M, Boulle, A, Calmy, A, Brinkhof, Martin, Dabis, F, Tweya, Hannock, Brinkhof, Martin, W.G., Keiser, Olivia, MacPhail, Patrick, MacPhail, P, Pujades-Rodriguez, Mar, Tuboi, S, Schechter, Mauro, Nash, Denis, Jahn, A, Braitstein, P, Boulle, Andrew, Dabis, François, Lüthy, R, Keiser, O, Lüthy, Ruedi, Sprinz, E, Tweya, H, Wood, Robin, Pujades-Rodriguez, M, ART-LINC of IeDEA Study Group, Calmy A, Schecter M, Tuboi S, Nash D, Jahn A, Tweya H, Boulle A, Lüthy R, Kumarasamy N, Keiser O, MacPhail P, Egger M, Brinkhof MW, Sprinz E, Pujades-Rodriguez M, Braitstein P, Dabis F, Wood R   +55 more
core   +2 more sources

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring. [PDF]

, 2012
BACKGROUND: The most recent World Health Organization (WHO) antiretroviral treatment guidelines recommend the inclusion of zidovudine (ZDV) or tenofovir (TDF) in first-line therapy.
Alec Miners, Valentina Cambiano (146513), von Wyl Viktor, Phillips, Andrew N, Andrew N Phillips, Jens Lundgren, Valentina Cambiano, Silvia Bertagnolio, Pillay Deenan, Pillay, Deenan, Deenan Pillay (7888), Bertagnolio, Silvia, Miners Alec, Michael R. Jordan (146520), Cambiano, Valentina, von Wyl, Viktor, Viktor von Wyl, Phillips Andrew N., Jordan, Michael R, Cambiano Valentina, Miners, Alec, Bertagnolio Silvia, Lundgren Jens, Andrew N. Phillips (146556), Lundgren, Jens, Alec Miners (146534), Viktor von Wyl (146506), Silvia Bertagnolio (57174), Michael R Jordan, Deenan Pillay, Jens Lundgren (146550), Jordan Michael R.   +31 more
core   +2 more sources